Lacosamide Hameln (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing hyper‑excitable neuronal membranes. This reduces repetitive neuronal firing and limits the spread of epileptiform activity, helping to control seizure episodes.

The specific dose and infusion rate of Lacosamide Hameln are determined by the prescribing clinician based on the patient’s clinical condition, age, weight, and renal function. The prescriber sets the appropriate regimen.

Lacosamide is classified as pregnancy category C, indicating that risk to the fetus cannot be ruled out. It should be used only if the potential benefit justifies the potential risk. Limited data are available for breastfeeding, so a risk‑benefit assessment is required.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from many traditional antiepileptics that target fast inactivation. This can provide additive seizure control when combined with other agents, and it often has a distinct side‑effect profile, making it a valuable option for refractory focal seizures.

Lacosamide Hameln must be stored at 2‑8 °C, protected from light, and should not be frozen or shaken. Keep the vials in the original packaging until use to maintain stability and sterility.

The product is supplied as an injectable solution for intravenous infusion. Administration is performed by a qualified healthcare professional, typically as a slow infusion over a prescribed period, following aseptic technique and appropriate monitoring.

Serious risks include cardiac arrhythmias such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, respiratory depression, and rare cases of anaphylaxis. Prompt recognition and medical intervention are essential if these events occur.

Patients with known hypersensitivity to lacosamide or any component of the formulation should avoid it. Caution is also advised for individuals with significant cardiac conduction disorders, severe renal impairment, or those taking interacting medications listed under major interactions.